Recurrent Uveitic Macular Edema Managed with Intravitreal Faricimab Injection

Overview

Journal J Ophthalmic Inflamm Infect

Publisher Springer

Specialty Ophthalmology

Date 2025 Mar 13

PMID 40080237

Authors

Negin Yavari

Dalia El Feky

Frances A Anover

Khiem Nguyen

Azadeh Mobasserian

Quan Dong Nguyen

Christopher Or

Affiliations

Soon will be listed here.

Abstract

Purpose: To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection.

Methods: Single case report from a tertiary referral center.

Observations: A 63-year-old Caucasian female presenting with recurrent UME due to birdshot chorioretinopathy (BSCR) in both eyes. UME had been treated with multiple agents including intravenous methylprednisone, posterior subtenons and intravitreal triamcinolone acetonide injection, dexamethasone implant, mycophenolate mofetil, and adalimumab with limited improvement and development of intolerance. Moreover, optical coherence tomography also revealed recurrence of UME with subretinal fluid in both eyes. After treatment with one dose of intravitreal faricimab injection, complete resolution of UME was achieved and maintained for three months.

Conclusion: The findings of this case hint towards the potential simultaneous effect of angiopoietin-2 blockade along with vascular endothelia growth factor A inhibition by faricimab in managing treatment-resistant UME. Nonetheless, more studies focusing on the role of intravitreal faricimab in UME are required.

References

Kawali A, Sanjay S, Mohan A, Mahendradas P, Shroff S, Shetty R . Intensive topical interferon therapy in uveitic macular edema. Indian J Ophthalmol. 2022; 70(8):2986-2989. PMC: 9672726. DOI: 10.4103/ijo.IJO_3210_21. View

Teper S . Update on the Management of Uveitic Macular Edema. J Clin Med. 2021; 10(18). PMC: 8470573. DOI: 10.3390/jcm10184133. View

Thorne J, Sugar E, Holbrook J, Burke A, Altaweel M, Vitale A . Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2018; 126(2):283-295. PMC: 6348060. DOI: 10.1016/j.ophtha.2018.08.021. View

Deuter C, Zierhut M, Igney-Oertel A, Xenitidis T, Feidt A, Sobolewska B . Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. Ocul Immunol Inflamm. 2016; 25(2):215-220. DOI: 10.3109/09273948.2015.1099680. View

Lowder C, Belfort Jr R, Lightman S, Foster C, Robinson M, Schiffman R . Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5):545-53. DOI: 10.1001/archophthalmol.2010.339. View

Acharya N, Vitale A, Sugar E, Holbrook J, Burke A, Thorne J . Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023; 130(9):914-923. PMC: 10524707. DOI: 10.1016/j.ophtha.2023.04.011. View

Heier J, Khanani A, Quezada Ruiz C, Basu K, Ferrone P, Brittain C . Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326):729-740. DOI: 10.1016/S0140-6736(22)00010-1. View

Khanani A, Aziz A, Khan H, Gupta A, Mojumder O, Saulebayeva A . The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023; 37(17):3574-3581. PMC: 10686385. DOI: 10.1038/s41433-023-02553-5. View

Shirley M . Faricimab: First Approval. Drugs. 2022; 82(7):825-830. DOI: 10.1007/s40265-022-01713-3. View

10.

Thomas J, Kim L, Albini T, Yeh S . Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis. Expert Rev Ophthalmol. 2022; 17(3):165-173. PMC: 9438525. DOI: 10.1080/17469899.2022.2114456. View

11.

Sahni J, Patel S, Dugel P, Khanani A, Jhaveri C, Wykoff C . Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019; 126(8):1155-1170. DOI: 10.1016/j.ophtha.2019.03.023. View

12.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

13.

Suzuki K, Iwata D, Namba K, Hase K, Hiraoka M, Murata M . Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis. PLoS One. 2023; 18(11):e0294745. PMC: 10683998. DOI: 10.1371/journal.pone.0294745. View

14.

Oshima Y, Deering T, Oshima S, Nambu H, Reddy P, Kaleko M . Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004; 199(3):412-7. DOI: 10.1002/jcp.10442. View

15.

Sharma A, Kumar N, Kuppermann B, Bandello F, Loewenstein A . Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2019; 34(5):802-804. PMC: 7182558. DOI: 10.1038/s41433-019-0670-1. View

16.

Eter N, Singh R, Abreu F, Asik K, Basu K, Baumal C . YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Ophthalmol Sci. 2022; 2(1):100111. PMC: 9559760. DOI: 10.1016/j.xops.2021.100111. View

17.

Bojikian K, Nobrega P, Roldan A, Forrest S, Tsukikawa M, Chen P . Incidence of and Risk Factors for Steroid Response After Cataract Surgery in Patients With and Without Glaucoma. J Glaucoma. 2021; 30(4):e159-e163. DOI: 10.1097/IJG.0000000000001785. View

18.

Roberti G, Oddone F, Agnifili L, Katsanos A, Michelessi M, Mastropasqua L . Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020; 65(4):458-472. DOI: 10.1016/j.survophthal.2020.01.002. View